Niedrig M - Search Results

1

Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study1.

Bühler S, Jaeger VK, Eperon G, Furrer H, Fux CA, Jansen S, Neumayr A, Rochat L, Schmid S, Schmidt-Chanasit J, Staehelin C, de Visser AW, Visser LG, Niedrig M, Hatz C. Bühler S, et al. Among authors: niedrig m. J Travel Med. 2020 Sep 26;27(6):taaa126. doi: 10.1093/jtm/taaa126. J Travel Med. 2020. PMID: 32729905

2

Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.

Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P, Bae HG, Litzba N, Staub T, Hatz C, Furrer H; Swiss HIV Cohort Study. Veit O, et al. Among authors: niedrig m. Clin Infect Dis. 2009 Mar 1;48(5):659-66. doi: 10.1086/597006. Clin Infect Dis. 2009. PMID: 19191654 Free article.

3

Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals.

Burkhard J, Ciurea A, Gabay C, Hasler P, Müller R, Niedrig M, Fehr J, Villiger P, Visser LG, de Visser AW, Walker UA, Hatz C, Bühler S. Burkhard J, et al. Among authors: niedrig m. Vaccine. 2020 Apr 23;38(19):3610-3617. doi: 10.1016/j.vaccine.2019.12.042. Epub 2020 Jan 5. Vaccine. 2020. PMID: 31911033

4

Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule.

Veit O, Domingo C, Niedrig M, Staehelin C, Sonderegger B, Héquet D, Stoeckle M, Calmy A, Schiffer V, Bernasconi E, Flury D, Hatz C, Zwahlen M, Furrer H; Swiss HIV Cohort Study. Veit O, et al. Among authors: niedrig m. Clin Infect Dis. 2018 Mar 19;66(7):1099-1108. doi: 10.1093/cid/cix960. Clin Infect Dis. 2018. PMID: 29140432 Free article.

5

Safety of 17D derived yellow fever vaccines.

Domingo C, Niedrig M. Domingo C, et al. Among authors: niedrig m. Expert Opin Drug Saf. 2009 Mar;8(2):211-21. doi: 10.1517/14740330902808086. Expert Opin Drug Saf. 2009. PMID: 19309249 Review.

6

External quality assessment studies for laboratory performance of molecular and serological diagnosis of Chikungunya virus infection.

Jacobsen S, Patel P, Schmidt-Chanasit J, Leparc-Goffart I, Teichmann A, Zeller H, Niedrig M. Jacobsen S, et al. Among authors: niedrig m. J Clin Virol. 2016 Mar;76:55-65. doi: 10.1016/j.jcv.2016.01.008. Epub 2016 Jan 12. J Clin Virol. 2016. PMID: 26828561 Free article.

7

Genome Sequences of West Nile Virus Reference Materials.

Roth H, Kreß J, Chudy M, Blümel J, Schmidt-Chanasit J, Cadar D, Niedrig M, Ferenczi E, Herrmann M, Baylis SA, Miskey C. Roth H, et al. Among authors: niedrig m. Microbiol Resour Announc. 2021 Oct 28;10(43):e0074021. doi: 10.1128/MRA.00740-21. Epub 2021 Oct 28. Microbiol Resour Announc. 2021. PMID: 34709054 Free PMC article.

8

The phylogeny of yellow fever virus 17D vaccines.

Stock NK, Boschetti N, Herzog C, Appelhans MS, Niedrig M. Stock NK, et al. Among authors: niedrig m. Vaccine. 2012 Feb 1;30(6):989-94. doi: 10.1016/j.vaccine.2011.12.057. Epub 2011 Dec 23. Vaccine. 2012. PMID: 22197965

9

Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.

Bae HG, Domingo C, Tenorio A, de Ory F, Muñoz J, Weber P, Teuwen DE, Niedrig M. Bae HG, et al. Among authors: niedrig m. J Infect Dis. 2008 Jun 1;197(11):1577-84. doi: 10.1086/587844. J Infect Dis. 2008. PMID: 18419548

10

Analysis of delayed TBE-vaccine booster after primary vaccination.

Aerssens A, Cochez C, Niedrig M, Heyman P, Kühlmann-Rabens I, Soentjens P. Aerssens A, et al. Among authors: niedrig m. J Travel Med. 2016 Feb 8;23(2):tav020. doi: 10.1093/jtm/tav020. Print 2016 Feb. J Travel Med. 2016. PMID: 26858269

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

222 results

Search Page